Precipio Launches HemeScreen, a Disruptive, Proprietary Molecular Test for Hematologic Cancers

Specialty cancer diagnostics company Precipio (NASDAQ:PRPO), today announced the commercial launch of HemeScreen, a novel proprietary test for mutations in hematologic cancers. Precipio is the first to offer a low cost, rapid molecular screening panel for hematologic mutations.

As quoted in the press release:

Screening tools allow laboratories to quickly and inexpensively rule out negative patient samples for mutations in critical cancer genes, eliminating the need to perform more complex, costly genetic testing with longer turnaround times for those patients.

Precipio’s new HemeScreen assay delivers results within hours (vs. industry TAT of 7-10 days), at a fraction of the cost of currently used genotyping technologies such as DNA sequencing and Taqman SNP genotyping.

The assay tests for mutations in the CALR, JAK2, JAK2 exon 12, and MPL genes. These genes are critically important to developing the clinical roadmap for the patient; however, the majority of patients do not present any of these mutations, with less than 20% of patient samples returning a positive result¹²³. For these markers, if the result is negative, no additional testing is required and results are reported immediately. If the assay identifies a mutation, the lab reverts to the original process, with additional testing via NGS or Taqman SNP genotyping to identify the specific mutation within that gene.

Click here to read the full press release.